Revance Therapeutics, Inc. Quarterly Stockholders' Equity Attributable to Parent in USD from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
Revance Therapeutics, Inc. quarterly Stockholders' Equity Attributable to Parent history and growth rate from Q4 2010 to Q3 2024.
  • Revance Therapeutics, Inc. Stockholders' Equity Attributable to Parent for the quarter ending September 30, 2024 was -$163M, a 53.5% decline year-over-year.
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 -$163M -$56.8M -53.5% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$130M -$157M -584% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$98.7M -$72M -270% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$152M -$164M -1303% Dec 31, 2023 10-Q 2024-11-07
Q3 2023 -$106M -$252M -173% Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $26.8M +$29.4M Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$26.7M -$52.2M -204% Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $12.6M -$55.9M -81.6% Dec 31, 2022 10-K 2024-02-28
Q3 2022 $146M +$25.6M +21.3% Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$2.63M -$189M -101% Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $25.5M -$219M -89.5% Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $68.5M -$306M -81.7% Dec 31, 2021 10-K 2024-02-28
Q3 2021 $120M -$253M -67.8% Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $186M -$69.5M -27.2% Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $244M -$64.1M -20.8% Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $374M +$149M +66% Dec 31, 2020 10-K 2024-02-28
Q3 2020 $373M +$222M +146% Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $256M +$67.2M +35.6% Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $308M +$87.3M +39.5% Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $225M +$79.9M +54.8% Dec 31, 2019 10-K 2023-02-28
Q3 2019 $151M -$30.8M -16.9% Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $189M -$21.3M -10.2% Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $221M -$15.5M -6.57% Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $146M -$123M -45.8% Dec 31, 2018 10-K 2022-02-28
Q3 2018 $182M +$40M +28.2% Sep 30, 2018 10-Q 2019-11-04
Q2 2018 $210M +$50.4M +31.6% Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $237M +$58M +32.4% Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $269M +$91.8M +51.8% Dec 31, 2017 10-K 2021-02-25
Q3 2017 $142M -$58.7M -29.2% Sep 30, 2017 10-Q 2017-11-03
Q2 2017 $159M -$56.4M -26.1% Jun 30, 2017 10-Q 2017-08-04
Q1 2017 $179M -$58.2M -24.6% Mar 31, 2017 10-Q 2017-05-09
Q4 2016 $177M -$76.2M -30.1% Dec 31, 2016 10-K 2020-02-26
Q3 2016 $201M +$58.4M +41% Sep 30, 2016 10-Q 2016-11-04
Q2 2016 $216M +$66.9M +45% Jun 30, 2016 10-Q 2016-08-05
Q1 2016 $237M +$73.4M +44.9% Mar 31, 2016 10-Q 2016-05-10
Q4 2015 $253M +$76.9M +43.6% Dec 31, 2015 10-K 2019-02-28
Q3 2015 $142M -$45.6M -24.2% Sep 30, 2015 10-Q 2015-11-10
Q2 2015 $149M -$49.7M -25% Jun 30, 2015 10-Q 2015-08-07
Q1 2015 $163M +$84.8M +108% Mar 31, 2015 10-Q 2015-05-14
Q4 2014 $176M +$334M Dec 31, 2014 10-K 2018-03-02
Q3 2014 $188M Sep 30, 2014 10-Q 2014-11-13
Q2 2014 $199M Jun 30, 2014 10-Q 2014-08-13
Q1 2014 $78.7M Mar 31, 2014 10-Q 2014-05-14
Q4 2013 -$158M +$59.2M +27.3% Dec 31, 2013 10-K 2017-02-28
Q4 2012 -$217M -$61.2M -39.4% Dec 31, 2012 10-K 2016-03-04
Q4 2011 -$155M -$44.1M -39.6% Dec 31, 2011 10-K 2015-03-04
Q4 2010 -$111M Dec 31, 2010 10-Q 2014-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.